Philadelphia Translocation in MDS: A Case Report and a Brief Review of the Literature Looking at Its Prevalence, Disease Progression, and Treatment Options

Table 2

Blast count and number of events.

Age	Gender	Classification	Cytogenetics	Bm blast%	Plt/mcL	Hgb g/dL	Time to progression	Treatment	Outcome	Reference
74	M	RCMD	44, XY, t(9 : 22) [4], 46,XY[16]- 46%	0	341	8.3	No progression	Dasatinib	Hospice after 7m following sepsis	[9]
55	F	RAEB I	45XX,−4,t(9; 22)(q34; q11.2)	6	10	10.3	No progression	Supportive care	Died in 1 month sepsis	[10]
31	M	RAEB II	44–45XY,der(4),−5,der(7),−7,−8,t(9; 22)(q34; q11.2),−15,+22	14	54	4.7	No progression	Supportive	Died in 1 week - IC bleed?	[10]
65	M	RAEB 2	44xy del 5,-7,-14,-16 + mar	18	n/a	n/a	No progression	None	Died in 1 m from lung cancer	[11]
67	M	RAEB1-> RAEB 2	45,XY,+3,−5,−7,−20,+mar,+mar/45,XY,	4	52	10.4	No progression	Imatinib for 2 weeks f/b supportive care	Died 1 yr from fungal pneumonia	[12]
			+3,−4,−8,−9,−11,−18,−20,−21,−21,+mar,+mar
61	M	MDS unclassifiable	46,XY,der(5; 12)(q10; q10)+mar[3]/46,XY[12] t(9; 22)by FISH in der(5; 12)	n/a	n/a	n/a	n/a	Imatinib, hydroxyurea, cytarabine	Died in 5m from resp failure	[13]
71	M	RAEB	46XX,der(12)t(12; 17)(p11.2; q11.2)[7]/46, XX[9]	10	54	9	To RAEBt in 5 m	Hydroxyurea	Died in 4 m from pneumonia	[14]
66	F	RAEB	47,XX,+8, t(9; 22; 16)(q34; q11.2,q23)[4]	2	275	7.5	Progressed to granulocytic sarcoma of skin in 9 m	Supportive care	Died 1 m later	[14]
59	M	RAEB	46,XY,t(9; 22)(q34; q11)	4	78	9.2	4 m to AML	Imatinib	Alive after HCT	[14]
67	F	RAEB 2	46,XX[1]/46,XX,t(9; 22)(q34; q11)[29]	10	114	11.5	NA	Conventional chemotherapy with rising blast % responded to imatinib.	Alive at 14 m after imatinib	[15]
73	M	RAEB	46 XT t(9 : 22),	8	n/a	n/a	CML in 2.5 yr f/b blast crisis in 3 m	Imatinib	Died with refractory CML and pneumonia	[16]
78	M	RAEB t	46,XY der (3), t(1 : 3)(p22:p14), t(9; 22)	22.2	29	9.8	n/a	Ara-C+daunorubicin->AraC+IDarubicin	Died from pneumonia 5 m after Dx	[17]
69	M	RAEBt	+Y, del5,q13q34,+8,+13,+14, p11+22, t922q34	14	46	8.1	2 m to AML	Vindesine f/b cytosine arabinoside, mitoxantrone, tenoposide	Died from pneumonia 5 m after Dx	[18]
64	M	RAEB	+8, t(9 : 22)(q34)- 46%	4	98	7.8	9 M to AML	Hydroxyurea f/b cyt ara-c, teniposide	Died from sepsis 9 m after Dx	[18]
30	M	MDS	46,XY[1]/46,XY,t(9; 22)(q34; q11)[45]	0.5	30	12.5	No progression	n/a	Died 2 years after due to intracranial bleeding	[19]
78	F	RAEB 2	46 XX, t(9; 22)(q 34; q 11)	11.7	21	8	5 m to AML	Transfusion, ubenimex	Died from pneumonia	[20]
73	M	MDS	46,XY[54]/46,XY,t(4; 6)(p15; p12),t(9; 22) (q34; q11)[6]	1	120	15.4	7 m to CMML	Supportive care	Died from bleeding 10 m after dx	[21]
85	M	RAEB	46,XY,t(9; 22)(q34; q11)	25	120	9.8	17 m to AML	Daunorubicine, cytarabine, 6-mercaptopurine. Prednisone f/b 6-mercaptopurine, hydroxyurea.	Died 21 m later	[22]
62	M	MDS	46,XY[?]/t(?; 11; 22)(?; q11; q11),t(9; 22)(q34; q11), −5,−7,+8,−12	8.2	3	11.9	3 m to RAEBt	Prednisolone and vit D3	Died 3 m later from pneumonia, bleeding	[23]
70	FM	RARS	46,XX[3]/46,XX,t(9q; 22q)[12]	n/a	316	9.5	No progression	Pyridoxine, nandrelone, folinic acid	Alive at 45 months	[24]
49	F	MDS	46 XX (3) t(9 : 22) 34 : 11	n/a	425	8.2	32M TO AML	Ara-C, 6-thioguainine, daunomycin	Died from pneumonia 1 m after AML	[25]
78	F	MDS-RARS	46,XX--> 46,XX,t(9; 22)(q34; q11)	14	152	10.2	26 m to CML blast crisis	Imatinib and nilotinib	Hematologic response on TKI	[26]
83	M	MDS-RCMD	46 XY--> 46,XY,t(9; 22)(q34; q11.2)[10]/46,XY[5]	<1	90	11.6	No progression	Imatinib-->dasatinib->nilotinib	Alive after 30 months	Case

M = male, F = female, RCMD = refractory cytopenia with multilineage dysplasia, RAEB = refractory anemia with excess blasts, RARS: refractory anemia with ringed sideroblasts, CML= chronic myeloid leukemia, CMML= chronic myelomonocytic leukemia, BM blast = bone marrow blast %, and Plt = Platelet.